SCHEMBL3684997

SCHEMBL3684997

C=CC(=O)OC(C)c1ccccc1C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.41
ESR1 P03372 1/20 0.40
ADRA2A P08913 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
ACP3 P15309 1/20 0.36
THRB P10828 2/20 0.35
ALDH1A1 P00352 1/20 0.35
TSHR P16473 2/20 0.34
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
THRA P10827 1/20 0.33
AKT1 P31749 1/20 0.32
ACHE P22303 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28200013 0.87 HCAR2 (0.40) HCAR2ESR1ADRA2AADRA2BADRA2C
SCHEMBL20102169 0.84 ESR1 (0.38) HCAR2ESR1KDM4EPOLBACP3
SCHEMBL1906054 0.83 GABRA1 (0.46) HCAR2POLBTHRBTSHRCYP1A2
SCHEMBL28268635 0.83 ESR1 (0.37) HCAR2ESR1KDM4EPOLBACP3
SCHEMBL16672653 0.82 HCAR2 (0.47) HCAR2ESR1ADRA2AADRA2BADRA2C
SCHEMBL16672646 0.82 HCAR2 (0.47) HCAR2ESR1ADRA2AADRA2BADRA2C
SCHEMBL8038710 0.82 HCAR2 (0.41) HCAR2KDM4ETHRBALDH1A1TSHR
SCHEMBL9819112 0.82 HCAR2 (0.41) HCAR2POLBTHRBTSHRCYP1A2
SCHEMBL7189816 0.82 POLB (0.45) HCAR2KDM4EPOLBTHRBTHRA
SCHEMBL20102165 0.81 HCAR2 (0.39) HCAR2KDM4ETHRBALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080145405-A1 Providing a clean device comprising a porous polymer core containing an ocular drug in it cavities and covered by a polymer shell permeable for passage of the drug(s); subjecting the device to a supercritical fluid to remove contaminants; sustained release; grafting or injection; vision defects BAUSCH & LOMB INCORPORATED 2008-06-19 US claimed
US-20070218104-A1 Rate controlled release of a pharmaceutical agent in a biodegradable device BAUSCH & LOMB INCORPORATION 2007-09-20 US claimed
US-20070218103-A1 Rate controlled release of a pharmaceutical agent in a biodegradable device BAUSCH & LOMB INCORPORATED 2007-09-20 US claimed
US-20020019492-A1 Method of making high refractive index ophthalmic device materials NOVARTIS AG (CH) 2002-02-14 US claimed
EP-4267708-B1 THERMALLY RESPONSIVE BRUSH POLYMERS HAVING A COPOLYMER BACKBONE AND COPOLYMER ARMS INFINEUM INT LTD (GB) 2025-07-02 EP disclosed
US-12281203-B2 Thermally responsive brush polymers having a copolymer backbone and copolymer arms INFINEUM INTERNATIONAL LIMITED (GB) 2025-04-22 US disclosed
US-20240309155-A1 Thermally Responsive Brush Polymers Having a Copolymer Backbone and Copolymer Arms INFINEUM INTERNATIONAL LIMITED (GB) 2024-09-19 US disclosed
EP-4267708-A1 THERMALLY RESPONSIVE BRUSH POLYMERS HAVING A COPOLYMER BACKBONE AND COPOLYMER ARMS Infineum International Limited (GB) 2023-11-01 EP disclosed
CN-116981758-A Thermally responsive brush polymers having a copolymer backbone and copolymer arms 英菲诺姆国际有限公司 2023-10-31 CN disclosed
WO-2022136384-A1 THERMALLY RESPONSIVE BRUSH POLYMERS HAVING A COPOLYMER BACKBONE AND COPOLYMER ARMS INFINEUM INTERNATIONAL LIMITED (GB) 2022-06-30 WO disclosed
EP-2869389-B1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME MITSUBISHI CHEM CORP (JP) 2019-11-13 EP disclosed
US-10320030-B2 Nonaqueous electrolyte solution and nonaqueous electrolyte battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2019-06-11 US disclosed
US-20080147021-A1 DRUG DELIVERY DEVICES BAUSCH & LOMB INCORPORATED 2008-06-19 US disclosed
US-20080002146-A1 BIOCOMPATIBLE, SURFACE MODIFIED MATERIALS BAUSCH & LOMB INCORPORATED 2008-01-03 US disclosed
US-20070218104-A1 Rate controlled release of a pharmaceutical agent in a biodegradable device BAUSCH & LOMB INCORPORATION 2007-09-20 US disclosed
US-20070218103-A1 Rate controlled release of a pharmaceutical agent in a biodegradable device BAUSCH & LOMB INCORPORATED 2007-09-20 US disclosed
US-5147867-A Bactericides, (carba)penicillins MERCK & CO., INC. (US) 1992-09-15 US disclosed
US-5145990-A Dehydropeptidase, carbapenicillin potentiation MERCK & CO., INC. (US) 1992-09-08 US disclosed
US-4962097-A IN COMBINATION WITH A CARBAPENEM OR PENEM ANTIBIOTIC MERCK & CO., INC. (US) 1990-10-09 US disclosed
EP-0366469-A2 Phosphorus containing enzyme inhibitors MERCK & CO. INC. (US) 1990-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070218104-A1 Rate controlled release of a pharmaceutical agent in a biodegradable device IDUA, ACMSD, MLEC HCAR2 29/4885ESR1 1489/4885ADRA2A 623/4885
US-20070218103-A1 Rate controlled release of a pharmaceutical agent in a biodegradable device IDUA, APEH, PAM HCAR2 48/4885ESR1 1770/4885ADRA2A 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.